Cogent Biosciences Stock Price To Sales

COGT Stock  USD 7.54  0.55  7.87%   
Cogent Biosciences fundamentals help investors to digest information that contributes to Cogent Biosciences' financial success or failures. It also enables traders to predict the movement of Cogent Stock. The fundamental analysis module provides a way to measure Cogent Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cogent Biosciences stock.
Last ReportedProjected for Next Year
Price To Sales Ratio 18.18  35.83 
Price To Sales Ratio is likely to gain to 35.83 in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cogent Biosciences Company Price To Sales Analysis

Cogent Biosciences' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

 = 

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Cogent Biosciences Price To Sales

    
  1,321 X  
Most of Cogent Biosciences' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cogent Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Cogent Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Cogent Biosciences is extremely important. It helps to project a fair market value of Cogent Stock properly, considering its historical fundamentals such as Price To Sales. Since Cogent Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cogent Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cogent Biosciences' interrelated accounts and indicators.
0.990.52-0.57-0.830.730.710.741.00.350.820.930.980.920.99-0.280.87
0.990.46-0.65-0.790.680.650.661.00.420.790.930.990.940.97-0.360.82
0.520.460.07-0.830.850.830.720.5-0.020.810.50.470.450.56-0.120.65
-0.57-0.650.070.24-0.040.090.09-0.62-0.8-0.25-0.56-0.68-0.77-0.480.77-0.14
-0.83-0.79-0.830.24-0.97-0.9-0.82-0.81-0.11-0.99-0.79-0.8-0.77-0.880.23-0.89
0.730.680.85-0.04-0.970.950.840.7-0.070.970.710.680.610.8-0.110.88
0.710.650.830.09-0.90.950.890.67-0.20.90.650.630.520.770.10.88
0.740.660.720.09-0.820.840.890.7-0.190.80.620.630.530.80.260.94
1.01.00.5-0.62-0.810.70.670.70.390.810.920.990.940.98-0.330.84
0.350.42-0.02-0.8-0.11-0.07-0.2-0.190.390.160.510.480.510.29-0.660.02
0.820.790.81-0.25-0.990.970.90.80.810.160.830.80.750.87-0.230.89
0.930.930.5-0.56-0.790.710.650.620.920.510.830.940.850.92-0.320.79
0.980.990.47-0.68-0.80.680.630.630.990.480.80.940.960.96-0.40.8
0.920.940.45-0.77-0.770.610.520.530.940.510.750.850.960.89-0.530.69
0.990.970.56-0.48-0.880.80.770.80.980.290.870.920.960.89-0.230.93
-0.28-0.36-0.120.770.23-0.110.10.26-0.33-0.66-0.23-0.32-0.4-0.53-0.230.04
0.870.820.65-0.14-0.890.880.880.940.840.020.890.790.80.690.930.04
Click cells to compare fundamentals

Cogent Price To Sales Historical Pattern

Today, most investors in Cogent Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cogent Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cogent Biosciences price to sales as a starting point in their analysis.
   Cogent Biosciences Price To Sales   
       Timeline  
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Competition

Cogent Price To Sales Ratio

Price To Sales Ratio

35.83

At this time, Cogent Biosciences' Price To Sales Ratio is comparatively stable compared to the past year.
Based on the latest financial disclosure, Cogent Biosciences has a Price To Sales of 1.32 K times. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The price to sales for all United States stocks is notably lower than that of the firm.

Cogent Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cogent Biosciences' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cogent Biosciences could also be used in its relative valuation, which is a method of valuing Cogent Biosciences by comparing valuation metrics of similar companies.
1.3K976.6685.1334.9253.1100%
Cogent Biosciences is currently under evaluation in price to sales category among its peers.

Cogent Biosciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of Cogent Biosciences from analyzing Cogent Biosciences' financial statements. These drivers represent accounts that assess Cogent Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cogent Biosciences' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap21.9M124.4M332.3M679.0M611.1M641.7M
Enterprise Value(9.4M)(112.5M)115.8M558.8M502.9M528.1M

Cogent Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cogent Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cogent Biosciences' managers, analysts, and investors.
56.4%
Environmental
64.4%
Governance
Social

Cogent Fundamentals

Return On Equity-1.0
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%
Return On Asset-0.54
Current Valuation604.92 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%
Shares Outstanding113.85 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%200%400%600%800%
Shares Owned By Insiders0.15 %
Shares Owned By Institutions99.84 %
Number Of Shares Shorted10.8 M
Price To Earning(5.03) X
Price To Book5.24 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%200%
Price To Sales1,321 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Gross Profit(121.63 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-200%0%200%400%600%
EBITDA(275.94 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%
Net Income(255.86 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%3,000%3,500%
Cash And Equivalents325.56 M
Cash Per Share4.95 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%0%20%40%
Total Debt17.47 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%200%
Debt To Equity0.09 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Current Ratio11.96 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%0%20%40%
Book Value Per Share1.32 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%
Cash Flow From Operations(207.79 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,200%-1,000%-800%-600%-400%-200%
Short Ratio6.99 X
Earnings Per Share(1.94) X
Price To Earnings To Growth(0.14) X
Target Price16.4
Beta0.031
Market Capitalization795.81 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-50%0%50%100%150%
Total Asset327.9 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%50%100%150%200%250%300%
Retained Earnings(859.48 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%3,000%
Working Capital240.76 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset37.62 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%200%250%300%
Current Liabilities21.06 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%500%
Net Asset327.9 M

About Cogent Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cogent Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cogent Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cogent Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cogent Stock Analysis

When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.